Axsome Therapeutics (19X) Ratios
Axsome Therapeutics Ratios
DE:19X's free cash flow for Q2 2026 was $-32.83M. For the 2026 fiscal year, DE:19X's free cash flow was increased by $121.00K and operating cash flow was $-32.95M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.55 | 2.11 | 3.63 | 2.54 | 3.75 |
| Quick Ratio | 1.48 | 2.04 | 3.52 | 2.50 | 3.75 |
| Cash Ratio | 0.85 | 1.37 | 2.78 | 2.08 | 3.75 |
| Solvency Ratio | -0.29 | -0.55 | -0.59 | -0.82 | -1.81 |
| Operating Cash Flow Ratio | -0.25 | -0.56 | -1.04 | -1.21 | -4.69 |
| Short-Term Operating Cash Flow Coverage | -1.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -12.52M | $ -26.42M | $ 107.00M | $ 23.72M | $ 14.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.35 | 0.34 | 0.32 | 0.29 | 0.57 |
| Debt-to-Equity Ratio | 2.73 | 3.38 | 0.98 | 0.86 | 3.18 |
| Debt-to-Capital Ratio | 0.73 | 0.77 | 0.49 | 0.46 | 0.76 |
| Long-Term Debt-to-Capital Ratio | 0.61 | 0.76 | 0.48 | 0.46 | 0.76 |
| Financial Leverage Ratio | 7.81 | 9.97 | 3.08 | 3.03 | 5.62 |
| Debt Service Coverage Ratio | -2.11 | -41.51 | -35.01 | -23.91 | -21.88 |
| Interest Coverage Ratio | -25.81 | -42.71 | -35.93 | -24.51 | -21.89 |
| Debt to Market Cap | 0.02 | 0.04 | 0.05 | 0.03 | 0.03 |
| Interest Debt Per Share | 4.98 | 4.16 | 4.24 | 2.51 | 1.47 |
| Net Debt to EBITDA | 0.49 | 0.45 | 0.89 | 0.61 | 0.29 |
| Profitability Margins | |||||
| Gross Profit Margin | 92.56% | 91.37% | 90.37% | 89.61% | 0.00% |
| EBIT Margin | -27.74% | -72.74% | -85.67% | -359.33% | 0.00% |
| EBITDA Margin | -26.32% | -70.68% | -83.15% | -350.53% | 0.00% |
| Operating Profit Margin | -26.51% | -72.74% | -85.67% | -359.33% | 0.00% |
| Pretax Profit Margin | -28.77% | -74.45% | -88.06% | -373.99% | 0.00% |
| Net Profit Margin | -28.69% | -74.47% | -88.41% | -373.99% | 0.00% |
| Continuous Operations Profit Margin | -28.69% | -74.47% | -88.41% | -373.99% | 0.00% |
| Net Income Per EBT | 99.71% | 100.03% | 100.40% | 100.00% | 100.00% |
| EBT Per EBIT | 108.55% | 102.34% | 102.78% | 104.08% | 104.57% |
| Return on Assets (ROA) | -26.55% | -50.52% | -40.67% | -56.45% | -148.55% |
| Return on Equity (ROE) | -207.46% | -503.76% | -125.27% | -170.81% | -834.29% |
| Return on Capital Employed (ROCE) | -54.42% | -82.91% | -51.59% | -76.54% | -192.69% |
| Return on Invested Capital (ROIC) | -43.95% | -82.12% | -51.44% | -76.40% | -190.86% |
| Return on Tangible Assets | -28.74% | -56.37% | -45.75% | -71.56% | -148.55% |
| Earnings Yield | -2.02% | -7.08% | -6.62% | -5.97% | -9.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.84 | 2.72 | 2.85 | 1.33 | 0.00 |
| Payables Turnover | 0.72 | 0.46 | 0.64 | 0.13 | 0.00 |
| Inventory Turnover | 1.70 | 2.12 | 1.72 | 1.20 | 0.00 |
| Fixed Asset Turnover | 30.61 | 64.64 | 35.52 | 43.82 | 0.00 |
| Asset Turnover | 0.93 | 0.68 | 0.46 | 0.15 | 0.00 |
| Working Capital Turnover Ratio | 2.75 | 1.24 | 1.05 | 0.47 | 0.00 |
| Cash Conversion Cycle | -160.74 | -482.28 | -229.81 | -2132.47 | 0.00 |
| Days of Sales Outstanding | 128.32 | 134.38 | 127.90 | 275.00 | 0.00 |
| Days of Inventory Outstanding | 214.78 | 172.42 | 211.94 | 303.35 | 0.00 |
| Days of Payables Outstanding | 503.83 | 789.09 | 569.65 | 2710.82 | 0.00 |
| Operating Cycle | 343.10 | 306.80 | 339.84 | 578.35 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.88 | -2.68 | -3.19 | -2.87 | -2.88 |
| Free Cash Flow Per Share | -1.89 | -2.69 | -3.21 | -2.88 | -2.89 |
| Dividend Paid and CapEx Coverage Ratio | -194.59 | -475.59 | -249.28 | -165.97 | -351.38 |
| Capital Expenditure Coverage Ratio | -194.59 | -475.59 | -249.28 | -165.97 | -351.38 |
| Operating Cash Flow Coverage Ratio | -0.39 | -0.67 | -0.78 | -1.23 | -2.18 |
| Operating Cash Flow to Sales Ratio | -0.15 | -0.33 | -0.54 | -2.33 | 0.00 |
| Free Cash Flow Yield | -1.03% | -3.17% | -4.03% | -3.74% | -7.64% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -49.63 | -14.13 | -15.11 | -16.76 | -10.90 |
| Price-to-Sales (P/S) Ratio | 14.23 | 10.51 | 13.36 | 62.67 | 0.00 |
| Price-to-Book (P/B) Ratio | 102.90 | 71.10 | 18.93 | 28.62 | 90.93 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -96.78 | -31.50 | -24.82 | -26.75 | -13.09 |
| Price-to-Operating Cash Flow Ratio | -97.27 | -31.57 | -24.92 | -26.91 | -13.13 |
| Price-to-Earnings Growth (PEG) Ratio | 1.29 | -1.03 | -1.04 | -0.51 | -0.48 |
| Enterprise Value Multiple | -53.57 | -14.42 | -15.18 | -17.27 | -11.11 |
| Enterprise Value | 9.00B | 3.93B | 3.42B | 3.03B | 1.38B |
| EV to EBITDA | -53.57 | -14.42 | -15.18 | -17.27 | -11.11 |
| EV to Sales | 14.10 | 10.19 | 12.62 | 60.55 | 0.00 |
| EV to Free Cash Flow | -95.91 | -30.55 | -23.45 | -25.85 | -12.76 |
| EV to Operating Cash Flow | -96.40 | -30.62 | -23.54 | -26.00 | -12.79 |
| Tangible Book Value Per Share | 0.72 | -0.04 | 2.77 | 0.97 | 0.42 |
| Shareholders’ Equity Per Share | 1.77 | 1.19 | 4.20 | 2.69 | 0.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 12.83 | 8.05 | 5.96 | 1.23 | 0.00 |
| Net Income Per Share | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.04 | 1.02 | 1.03 | 1.04 | 1.05 |
| Research & Development to Revenue | 0.29 | 0.49 | 0.36 | 1.16 | 0.00 |
| SG&A to Revenue | 0.89 | 1.07 | 0.82 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.15 | 0.22 | 0.23 | 0.75 | 0.00 |
| Income Quality | 0.51 | 0.45 | 0.61 | 0.62 | 0.83 |
Currency in USD